Search

Your search keyword '"Hautefeuille V"' showing total 166 results

Search Constraints

Start Over You searched for: Author "Hautefeuille V" Remove constraint Author: "Hautefeuille V"
166 results on '"Hautefeuille V"'

Search Results

1. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study

2. Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

5. 608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort

6. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

7. Sporadic non-functional neuroendocrine pancreatic incidentalomas (NF-NEI) ≤ 2 cm: risk of progression over 3 years. Results of the prospective multicenter French national study IPANEMA

8. A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn’s Disease: A Population-based Study

9. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn′s Disease: A French Population-Based Study

13. 387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study

17. 1761P Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC+ network

18. 1760P Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC+ network

20. 1447P Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

21. 562P Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28

23. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study

24. Caractérisation des patients progressifs pendant la lutathérapie

25. 1487TiP A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM – D17-01 PRODIGE 63 STUDY)

26. 429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status

27. LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

31. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

33. 443P First-line chemotherapy with raltitrexed in metastatic colorectal cancer: An AGEO multicentre study

34. 522TiP PRODIGE 71 - BEVAMAINT: A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer

35. 1454P PARAFIRIGAST: Paclitaxel/ramucirumab versus FOLFIRI as second line chemotherapy of metastatic gastric cancer: An AGEO multicenter comparative study with a propensity score analysis

36. PD-6 Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGEO study

37. LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

38. FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort

39. BRAF-mutated colorectal metastases: What is the benefit of liver surgery? Results from a cohort of 91 patients

42. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases

43. Prise en charge endoscopique de 345 tumeurs neuro-endocrines du rectum

44. Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort

46. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

48. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988–2011): A Population-Based Study of French Adolescents

49. A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability

Catalog

Books, media, physical & digital resources